Pharmaceutical Research and Manufacturers of America

Oregon Prescription Drug Program Bill Dies a Second Death

The Lund Report
For the second legislative session in a row, the bill could not overcome opposition from the insurance industry

March 15, 2012—Legislation requiring state agencies to purchase their prescription drugs through the Oregon Prescription Drug Program (OPDP) once again was unable to overcome staunch opposition from the pharmaceutical industry and insurance lobbyists.

 

Subscribe to Pharmaceutical Research and Manufacturers of America